Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega-3 Augmentation for Depression in CHD
NCT02021669Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- May 2014
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eicosapentaenoic acid in major depressive disorder (MDD), sponsored by Washington University School of Medicine. Started May 2014; status: completed.
02
Drugs
eicosapentaenoic acid
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02021669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02021669.